Transcription Factor Binding and Individual Genetic Risk of Valproate Teratogenicity.

doi:10.1212/WNL.0000000000214570

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Transcription Factor Binding and Individual Genetic Risk of Valproate Teratogenicity.

Neurology - 10 Feb 2026

Anderson Alison, Perucca Piero, Vianca Elena, Sandvik Daniel, Antonic-Baker Ana, Krause Roland, Jazayeri Dana, Hitchcock Alison, Graham Janet, Todaro Marian, Tomson Torbjörn, Battino Dina, Perucca Emilio, Ferri Meritxell Martinez, Rochtus Anne, Lagae Lieven, Canevini Maria Paola, Zambrelli Elena, Campbell Ellenr, Rakitin Aleksei, Koeleman Bobby, Scheffer Ingrid E, Berkovic Samuel F, Kwan Patrick, Sisodiya Sanjay M, Craig John J, Vajda Frank J, O'Brien Terence J

Abstract excerpt

BACKGROUND AND OBJECTIVES: Valproate (VPA) use during pregnancy is associated with a wide range of structural birth defects, but not all exposed children are affected and there is evidence for a genetic predisposition. The development of a pharmacogenomic biomarker test that can be used for preconception counseling, allowing access to women unnecessarily denied VPA treatment because of concern about teratogenic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Abnormalities, Drug-Induced

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Anticonvulsants

Share to Epilepsy

Share to Genetic Predisposition to Disease

Share to Pregnancy

Share to Teratogens

Share to Transcription Factors

Share to Valproic Acid

Source

Open in PubMed

Identifiers

PMID: 41534013
DOI: 10.1212/WNL.0000000000214570

Genes

EP300
TF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Transcription Factor Binding and Individual Genetic Risk of Valproate Teratogenicity.PMID 41534013Read ↗

Transcription factor binding and individual genetic risk for valproate teratogenicitySemantic proximity Read ↗

Integrative genomics reveals pathogenic mediator of valproate-induced neurodevelopmental disabilitySemantic proximity Read ↗

Transgenerational adverse effects of valproate? A patient report from 90 affected familiesSemantic proximity Read ↗

Diagnosis and management of individuals with Fetal Valproate Spectrum Disorder; a consensus statement from the European Reference Network for Congenital Malformations and Intellectual DisabilitySemantic proximity Read ↗

Antiepileptic medication during pregnancy: does fetal genotype affect outcome?Semantic proximity Read ↗

Integrative analysis of noncoding mutations identifies the druggable genome in preterm birth.Semantic proximity Read ↗

Assessing molecular gene by treatment interactions using a population of neural progenitors exposed to valproic acid and lithium.Semantic proximity Read ↗

Association of valproate‐induced teratogenesis with histone deacetylase inhibition in vivoSemantic proximity Read ↗

Risk of Adverse Pregnancy Outcomes Associated with Sodium Valproate(VPA): A Disproportionality Analysis Using the FDA Adverse Event Reporting System (FAERS)Semantic proximity Read ↗

Antiseizure medication use during pregnancy and children’s neurodevelopmental outcomesSemantic proximity Read ↗

Assessing molecular gene by treatment interactions using a population of neural progenitors exposed to valproic acid and lithiumSemantic proximity Read ↗

Antiepileptic Drug Teratogenicity and De Novo Genetic Variation Load.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.